Hepatology

Papers
(The H4-Index of Hepatology is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis1799
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive1579
Reply1431
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease908
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies461
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death385
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?297
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis224
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8213
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST212
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation208
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients208
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis185
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis179
Efficacy and safety of infliximab in patients with autoimmune hepatitis177
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma175
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study169
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH169
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency162
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1159
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention143
Cover Image141
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model140
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma131
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension130
Alan Hofmann (1931‐2021): A career well spent understanding bile acids126
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice125
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells124
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s122
Letter to the editor: The precise relationship between MELD and survival without a liver transplant122
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!122
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks117
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol114
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction110
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals109
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy109
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis108
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC105
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates105
Reply: Medications promoting abstinence in alcohol-associated cirrhosis104
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury104
Late-Breaking Abstracts103
Access to technology to support telehealth in areas without specialty care for liver disease102
Plasma proteomic signature of fatty liver disease: The Rotterdam Study101
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor101
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression99
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway99
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet99
Regulatory role and translational potential of CCL11 in liver fibrosis98
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis98
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution94
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice91
89
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease89
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis86
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma86
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma85
85
Reply84
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis84
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms84
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis84
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma83
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?83
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement82
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation81
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease80
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study80
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH80
Metabolic dysfunction-associated steatotic liver disease and the heart79
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination79
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment78
Much more needed in natural history of Alagille syndrome78
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans76
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity76
Therapeutic manipulation of the microbiome in liver disease75
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm75
Genes that fit just right: Unzipping the genome of fatty liver disease75
2.1882040500641